Markets and sells insurance products and services in the United States. Provides commercial risk management solutions for mid-to-large size businesses. Now — the numbers.
That much dependence is a risk in itself: if this one line weakens, the whole company feels it directly.
The company closed last year at a loss: costs ran above sales. The picture changes only if spending is reined in.
Average growth of 28% a year over the last 4 years. Red columns mark years that ended in a loss.
At this burn rate the cash pile isn’t the pressing question — for now, time is on the company’s side.
This company is not turning a profit, so the market is pricing its sales instead: 1.4× for every dollar of annual revenue.
Analysts' average target sits 5% below today's price.
The stock trades 22% below its peak. The market has trimmed its expectations for the company.
Over the last 4 years, sales grew about 28% a year on average.
The company sells $1.5B a year; the problem isn’t sales — it’s costs running above that number.
It pays out $0.50 per share each year — regular cash for whoever holds the stock.
A loss of $33.8M against $1.5B in annual sales.
Since the drop from its peak, buyer appetite hasn’t come back.
We don’t have a report card for this stock yet — the data isn’t mature enough to grade. No grade is information too: it means the evidence is thin.
One-line summary: few numbers, an untested story. Keep watching.